Literature DB >> 22424146

Short-term clinical outcomes among treatment-experienced HIV-positive patients with early low level viremia.

Chun Chao, Beth Tang, William Towner, Michael J Silverberg, Leo Hurley, Michael Horberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22424146      PMCID： PMC3335108          DOI： 10.1089/apc.2012.0035

Source DB:  PubMed          Journal:  AIDS Patient Care STDS        ISSN： 1087-2914            Impact factor:   5.078


× No keyword cloud information.
  7 in total

1.  CD4+ T-cell recovery and clinical outcome in HIV-1-infected patients exposed to multiple antiretroviral regimens: partial control of viremia is associated with favorable outcome.

Authors:  L Brigido; R Rodrigues; J Casseb; R M Custodio; L A M Fonseca; M Sanchez; A J S Duarte
Journal:  AIDS Patient Care STDS       Date:  2004-04       Impact factor: 5.078

2.  Is moderate HIV viremia associated with a higher risk of clinical progression in HIV-infected people treated with highly active antiretroviral therapy: evidence from the Italian cohort of antiretroviral-naive patients study.

Authors:  Rita Murri; Alessandro Cozzi Lepri; Paola Cicconi; Antonio Poggio; Massimo Arlotti; Giulia Tositti; Domenico Santoro; Maria Luisa Soranzo; Giuliano Rizzardini; Vincenzo Colangeli; Maria Montroni; Antonella D'Arminio Monforte
Journal:  J Acquir Immune Defic Syndr       Date:  2006-01-01       Impact factor: 3.731

3.  Adherence to protease inhibitor therapy and outcomes in patients with HIV infection.

Authors:  D L Paterson; S Swindells; J Mohr; M Brester; E N Vergis; C Squier; M M Wagener; N Singh
Journal:  Ann Intern Med       Date:  2000-07-04       Impact factor: 25.391

4.  Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users.

Authors:  Patrick M Tarwater; Joel E Gallant; John W Mellors; Mary E Gore; John P Phair; Roger Detels; Joseph B Margolick; Alvaro Muñoz
Journal:  AIDS       Date:  2004-12-03       Impact factor: 4.177

5.  Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115.

Authors:  Allan R Tenorio; Hongyu Jiang; Yu Zheng; Barbara Bastow; Daniel R Kuritzkes; John A Bartlett; Steven G Deeks; Alan L Landay; Sharon A Riddler
Journal:  AIDS Res Hum Retroviruses       Date:  2009-02       Impact factor: 2.205

6.  Effect of persistent moderate viremia on disease progression during HIV therapy.

Authors:  Stephen P Raffanti; Jennifer S Fusco; Beth H Sherrill; Nellie I Hansen; Amy C Justice; Richard D'Aquila; Wendy J Mangialardi; Gregory P Fusco
Journal:  J Acquir Immune Defic Syndr       Date:  2004-09-01       Impact factor: 3.731

Review 7.  Low-level viremia in HIV-1 infection: consequences and implications for switching to a new regimen.

Authors:  Calvin Cohen
Journal:  HIV Clin Trials       Date:  2009 Mar-Apr
  7 in total
  3 in total

1.  HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure.

Authors:  Luke C Swenson; Jeong Eun Min; Conan K Woods; Eric Cai; Jonathan Z Li; Julio S G Montaner; P Richard Harrigan; Alejandro Gonzalez-Serna
Journal:  AIDS       Date:  2014-05-15       Impact factor: 4.177

2.  Persistent Low-level Viremia While on Antiretroviral Therapy Is an Independent Risk Factor for Virologic Failure.

Authors:  Christie Joya; Seung Hyun Won; Christina Schofield; Tahaniyat Lalani; Ryan C Maves; Karl Kronmann; Robert Deiss; Jason Okulicz; Brian K Agan; Anuradha Ganesan
Journal:  Clin Infect Dis       Date:  2019-11-27       Impact factor: 9.079

3.  The significance of low-level viraemia in diverse settings: analysis of the Treat Asia HIV Observational Database (TAHOD) and the Australian HIV Observational Database (AHOD).

Authors:  R Kanapathipillai; H McManus; D D Cuong; O T Ng; N V Kinh; M Giles; T Read; I Woolley
Journal:  HIV Med       Date:  2014-01-26       Impact factor: 3.180
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.